ASCO® GI 2025 Insights: Impact of UGT1A1*28 Polymorphism on Treatment Tolerability in mPDAC Patients Receiving NALIRIFOX - NAPOLI-3 Trial | VuMedi

Find latest Pancreatic Cancer videos · 100+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

10 seconds

Playback speed

This video is featured in the Insights from 2025 ASCO® GI Annual Meeting

Insights from 2025 ASCO® GI Annual Meeting

ASCO® GI 2025 Insights: Impact of UGT1A1*28 Polymorphism on Treatment Tolerability in mPDAC Patients Receiving NALIRIFOX - NAPOLI-3 Trial

By Insights from 2025 ASCO® GI Annual Meeting FEATURING Maen Abdelrahim

By Insights from 2025 ASCO® GI Annual Meeting FEATURING Maen Abdelrahim

183 views

February 6, 2025

Comments 0

Login to view comments. Click here to Login